CrystalGenomics will provide new pharmaceutical candidate compounds while Bausch & Lomb will develop product formulations, conduct pre-clinical and clinical studies, and bring the products to market.
Praveen Tyle, chief scientific officer of Bausch & Lomb, said: “We believe this collaboration has the potential to extend our leadership in anti-inflammatory ophthalmic pharmaceuticals, especially with CrystalGenomics’s unique 3D structure-based optimization technology for compound discovery.”